Thank you for the overview of the VDA arena. This excerpt caught my attention:
“Data from a Phase Ib trial with CA4P plus the approved VEGF inhibitor Avastin… should become known in the third quarter of this year, and positive results would lead to a Phase II study testing a quadruplet combo regimen against NSCLC in the second half.”
I’m going to go out on a limb and predict that this quadruplet regimen (Avastin + CA4P + dual chemo) will prove to be too toxic, and that such a regimen will never be used commercially. Regards, Dew
Market Data 
Markets 
AI
